Efficacy and safety of arbidol (umifenovir) in patients with COVID‐19: A systematic review and meta‐analysis
Abstract Objective To provide the latest evidence for the efficacy and safety of arbidol (umifenovir) in COVID‐19 treatment. Methods A literature systematic search was carried out in PubMed, Cochrane Library, Embase, and medRxiv up to May 2021. The Cochrane risk of bias tool and Newcastle–Ottawa sca...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-12-01
|
| Series: | Immunity, Inflammation and Disease |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/iid3.502 |
| _version_ | 1818931160430936064 |
|---|---|
| author | Behnam Amani Bahman Amani Sara Zareei Mahsa Zareei |
| author_facet | Behnam Amani Bahman Amani Sara Zareei Mahsa Zareei |
| author_sort | Behnam Amani |
| collection | DOAJ |
| description | Abstract Objective To provide the latest evidence for the efficacy and safety of arbidol (umifenovir) in COVID‐19 treatment. Methods A literature systematic search was carried out in PubMed, Cochrane Library, Embase, and medRxiv up to May 2021. The Cochrane risk of bias tool and Newcastle–Ottawa scale were used to assess the quality of included studies. Meta‐analysis was performed using RevMan 5.3. Results Sixteen studies were met the inclusion criteria. No significant difference was observed between arbidol and non‐antiviral treatment groups neither for primary outcomes, including the negative rate of PCR (NR‐PCR) on Day 7 (risk ratio [RR]: 0.94; 95% confidence interval (CI): 0.78–1.14) and Day 14 (RR: 1.10; 95% CI: 0.96–1.25), and PCR negative conversion time (PCR‐NCT; mean difference [MD]: 0.74; 95% CI: −0.87 to 2.34), nor secondary outcomes (p > .05). However, arbidol was associated with higher adverse events (RR: 2.24; 95% CI: 1.06–4.73). Compared with lopinavir/ritonavir, arbidol showed better efficacy for primary outcomes (p < .05). Adding arbidol to lopinavir/ritonavir also led to better efficacy in terms of NR‐PCR on Day 7 and PCR‐NCT (p < .05). There was no significant difference between arbidol and chloroquine in primary outcomes (p > .05). No remarkable therapeutic effect was observed between arbidol and other agents (p > .05). Conclusion The present meta‐analysis showed no significant benefit of using arbidol compared with non‐antiviral treatment or other therapeutic agents against COVID‐19 disease. High‐quality studies are needed to establish the efficacy and safety of arbidol for COVID‐19. |
| first_indexed | 2024-12-20T04:12:10Z |
| format | Article |
| id | doaj.art-5c8053bcce894c5ca01afc66ae041c69 |
| institution | Directory Open Access Journal |
| issn | 2050-4527 |
| language | English |
| last_indexed | 2024-12-20T04:12:10Z |
| publishDate | 2021-12-01 |
| publisher | Wiley |
| record_format | Article |
| series | Immunity, Inflammation and Disease |
| spelling | doaj.art-5c8053bcce894c5ca01afc66ae041c692022-12-21T19:53:52ZengWileyImmunity, Inflammation and Disease2050-45272021-12-01941197120810.1002/iid3.502Efficacy and safety of arbidol (umifenovir) in patients with COVID‐19: A systematic review and meta‐analysisBehnam Amani0Bahman Amani1Sara Zareei2Mahsa Zareei3Department of Health Management and Economics, School of Public Health Tehran University of Medical Sciences Tehran IranHealth Management and Economics Research Center, Health Management Research Institute Iran University of Medical Sciences Tehran IranDepartment of Cell & Molecular Biology, Faculty of Biological Sciences Kharazmi University Tehran IranDepartment of Health Services Management, School of Health Management and Information Sciences Iran University of Medical Sciences Tehran IranAbstract Objective To provide the latest evidence for the efficacy and safety of arbidol (umifenovir) in COVID‐19 treatment. Methods A literature systematic search was carried out in PubMed, Cochrane Library, Embase, and medRxiv up to May 2021. The Cochrane risk of bias tool and Newcastle–Ottawa scale were used to assess the quality of included studies. Meta‐analysis was performed using RevMan 5.3. Results Sixteen studies were met the inclusion criteria. No significant difference was observed between arbidol and non‐antiviral treatment groups neither for primary outcomes, including the negative rate of PCR (NR‐PCR) on Day 7 (risk ratio [RR]: 0.94; 95% confidence interval (CI): 0.78–1.14) and Day 14 (RR: 1.10; 95% CI: 0.96–1.25), and PCR negative conversion time (PCR‐NCT; mean difference [MD]: 0.74; 95% CI: −0.87 to 2.34), nor secondary outcomes (p > .05). However, arbidol was associated with higher adverse events (RR: 2.24; 95% CI: 1.06–4.73). Compared with lopinavir/ritonavir, arbidol showed better efficacy for primary outcomes (p < .05). Adding arbidol to lopinavir/ritonavir also led to better efficacy in terms of NR‐PCR on Day 7 and PCR‐NCT (p < .05). There was no significant difference between arbidol and chloroquine in primary outcomes (p > .05). No remarkable therapeutic effect was observed between arbidol and other agents (p > .05). Conclusion The present meta‐analysis showed no significant benefit of using arbidol compared with non‐antiviral treatment or other therapeutic agents against COVID‐19 disease. High‐quality studies are needed to establish the efficacy and safety of arbidol for COVID‐19.https://doi.org/10.1002/iid3.5022019 novel coronavirus infection2019‐nCoV infectionarbidolcoronavirusnovel coronavirusumifenovir |
| spellingShingle | Behnam Amani Bahman Amani Sara Zareei Mahsa Zareei Efficacy and safety of arbidol (umifenovir) in patients with COVID‐19: A systematic review and meta‐analysis Immunity, Inflammation and Disease 2019 novel coronavirus infection 2019‐nCoV infection arbidol coronavirus novel coronavirus umifenovir |
| title | Efficacy and safety of arbidol (umifenovir) in patients with COVID‐19: A systematic review and meta‐analysis |
| title_full | Efficacy and safety of arbidol (umifenovir) in patients with COVID‐19: A systematic review and meta‐analysis |
| title_fullStr | Efficacy and safety of arbidol (umifenovir) in patients with COVID‐19: A systematic review and meta‐analysis |
| title_full_unstemmed | Efficacy and safety of arbidol (umifenovir) in patients with COVID‐19: A systematic review and meta‐analysis |
| title_short | Efficacy and safety of arbidol (umifenovir) in patients with COVID‐19: A systematic review and meta‐analysis |
| title_sort | efficacy and safety of arbidol umifenovir in patients with covid 19 a systematic review and meta analysis |
| topic | 2019 novel coronavirus infection 2019‐nCoV infection arbidol coronavirus novel coronavirus umifenovir |
| url | https://doi.org/10.1002/iid3.502 |
| work_keys_str_mv | AT behnamamani efficacyandsafetyofarbidolumifenovirinpatientswithcovid19asystematicreviewandmetaanalysis AT bahmanamani efficacyandsafetyofarbidolumifenovirinpatientswithcovid19asystematicreviewandmetaanalysis AT sarazareei efficacyandsafetyofarbidolumifenovirinpatientswithcovid19asystematicreviewandmetaanalysis AT mahsazareei efficacyandsafetyofarbidolumifenovirinpatientswithcovid19asystematicreviewandmetaanalysis |